Online citations, reference lists, and bibliographies.
← Back to Search

Anti-osteoclastic Agent, Denosumab, For A Giant Cell Tumor Of The Bone With Concurrent Paget's Disease: A Case Report

Takaaki Tanaka, J. Slavin, S. Mclachlan, P. Choong
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Paget's disease of the bone may predispose the development of malignant bone tumors such as osteosarcoma. Giant cell tumor (GCT) as a consequence of Paget's disease is rare. Bone GCT is characterized by rapid growth, the destruction of bone, extension to the surrounding soft tissue and abnormal bone turnover caused by an abnormality of the receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) pathway. Denosumab is a RANK-RANKL inhibitor, which is used to treat osteoporosis and bone GCT. In the current study, a 60-year-old male presented with severe pain located between the right thigh and the knee. The patient could not bear weight on the affected leg. The patient had suffered from Paget's disease for 15 years. The complications from Paget's disease included degenerative hip disease, for which the patient underwent a right total hip replacement. A right periacetabular lesion was identified and confirmed as Paget's disease-induced GCT by needle biopsy. A positron emission tomography (PET) scan revealed significant tumor metabolic activity. Subsequent to obtaining informed consent, the patient started treatment with denosumab. A total of 2.5 months after starting denosumab, a PET scan showed no residual pathological uptake at the site of the previously identified large PET avid tumor. After 1 year, the patient exhibited a satisfactory clinical improvement. In conclusion, treatment with denosumab markedly reduced the size of the hemi-pelvic GCT and led to a complete metabolic response.
This paper references
10.1016/s0140-6736(56)91979-1
Sarcomas of bone.
M. Sherman (1963)
10.1016/S0022-5347(17)47464-7
Neoplasms Arising in Paget’s Disease of Bone: A Study of 82 Cases
H. Haibach (1985)
Paget’s disease of the hip
J. Parvizi (2004)
10.1097/01.blo.0000180053.99840.27
Paget’s Sarcoma: A Historical and Outcome Review
H. Mankin (2005)
10.1056/NEJMCP060278
Paget's disease of bone
M. Whyte (2006)
Sarcomas of bone In cancer: Principles and practices of oncology. 8th edition
M Malawer (2008)
Sarcomas of bone. In cancer: Principles and practices of oncology
M Malawer (2008)
10.1016/J.BONE.2012.01.020
Paget's disease of the bone after treatment with Denosumab: a case report.
P. Schwarz (2012)
10.1210/jc.2013-1143
Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.
C. Grasemann (2013)
10.3747/co.20.1497
Denosumab and giant cell tumour of bone-a review and future management considerations.
S. F. Xu (2013)
10.1056/NEJMcp1204713
Clinical practice. Paget's disease of bone.
S. Ralston (2013)
10.2106/JBJS.M.01332
A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
I. Mak (2014)
10.1210/jc.2013-3762
Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene).
S. Polyzos (2014)
10.1007/s11864-014-0289-1
Giant Cell Tumor of Bone: Current Treatment Options
K. Skubitz (2014)
10.1093/annonc/mdv307
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial
T. Ueda (2015)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar